耐火性焦点演变为类似伦诺克斯-加斯托综合征的症状
Thi Hong Phan Nguyen1, Vi-Huong Nguyen-Michel2,3, Isabelle Gourfinkel-An2,4
1Rehabilitation Unit, AP-HP, Pitie-Salpêtrière Hospital, 75013, Paris, France.
Journal of neurology
|November 17, 2025
概括
焦点性可以发展为类似伦诺克斯-加斯托综合征 (LGS) 的特征,其特征是特定的电临床模式. 在LGS类患者的早期鉴定和干预可以带来更好的结果.
科学领域:
- 发病学 (Epileptology) 是一个专业的学科.
- 临床神经学 临床神经学
- 神经生理学 神经生理学
背景情况:
- 焦点可以演变为类似伦诺克斯-加斯托综合征 (LGS) 的情况.
- 这种进展涉及特定的电临床变化随着时间的推移.
- 了解LGS类患者对于将他们与经典LGS区分开来至关重要.
研究的目的:
- 描述患有LGS类综合征的患者的电临床概况.
- 为了将LGS类患者与经典LGS进行比较.
- 确定区分LGS类型和LGS的特征.
主要方法:
- 对2130名接受视频EEG监测的成年患者 (2002-2024) 的回顾性分析.
- 根据不良进展的焦点,泛发性快速活动 (GPFA) 和其他LGS标准 (强力/无力发作,认知/行为回归,扩散缓慢的尖和波) 定义的LGS类.
- 根据满足所有LGS标准,将LGS样患者分为全谱或部分谱.
主要成果:
- 34名患者 (1.6%) 符合LGS类标准,中位数发作发作时间为10.5年,持续时间为15.5年.
- 与经典的LGS相比,LGS类患者的发病时间较晚,认知回归率较低,EEG特征明显 (不对称的GPFA,成年时的SSW).
- 在69%的LGS类病例中观察到有利的结果,这表明潜在的可逆性.
结论:
- 从焦点到LGS类综合征的演变表明了病理连续性.
- 早期识别LGS型患者对于及时进行治疗调整至关重要.
- 干预可以帮助预防发症患者的不良结果.
相关概念视频
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Potassium Channel Activators
613
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
613
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Glutamate Antagonists
865
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
865
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
799
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
799


